Latest Iovance Biotherapeutics News & Updates

See the latest news and media coverage for Iovance. We track all announcements, press releases, and industry mentions in real time, all in one place.

Iovance Biotherapeutics (Iovance)

Biopharmaceutical company developing and commercializing cancer immunotherapies

iovance.com

Headquarters: San Carlos, United States
Founded year: 2007
Company type: Public company
Number of employees: 900–1,000
Industry: Pharmaceuticals

Last updated Today

Latest news about Iovance Biotherapeutics (Iovance)

In short: Iovance reported record quarterly revenues and secured international regulatory approvals for its melanoma cell therapy, Amtagvi.

Company announcements

August 6 Iovance

Iovance reports record second quarter 2026 revenue of ~$99M

Total revenue increased 66% year-over-year, gross margin reached 56%, and FDA granted Fast Track for lifileucel in soft tissue sarcomas.

June 5 Iovance

Iovance Biotherapeutics announces FDA clearance for IOV-5001 IND

The next-generation IL-12 tethered TIL therapy will be evaluated in a Phase 1/2 basket trial for advanced solid tumors, with enrollment starting in H2 2026.

June 3 Iovance

Iovance's Amtagvi granted approval for advanced melanoma in Australia

The Therapeutic Goods Administration approved the tumor-derived autologous T cell immunotherapy for previously treated advanced melanoma, marking Iovance's third marketing authorization.

May 7 Iovance

Iovance reports Q1 2026 revenue growth of 45%

The company guides Q2 2026 revenue to $86-88M and full-year to $350-370M, with a 40% confirmed response rate in endometrial cancer.

Media coverage

September 19 Yahoo Finance

Iovance Biotherapeutics (IOVA) Is Up 19.2% After Record Q2 Amtagvi Revenue And TIL Pipeline Expansion

Iovance Biotherapeutics recently reported record second-quarter results, generating nearly US$100 million in revenue with a 56% margin, while rapidly expanding access to its Amtagvi TIL...

September 17 Yahoo Finance

IOVA Stock Has Gained More Than 21% In Four Sessions, And Barclays Sees Another 52% Upside Potential - Here’s Why

Barclays raised Iovance’s price target to $15 from $13 while maintaining an ‘Overweight’ rating, acc...

September 15 Yahoo Finance

IOVA Flags Year-End Data Slate After Record Amtagvi Quarter, Highlights ‘Clear Line Of Sight To Profitability’

Iovance executive Brian Gastman said on Tuesday at a conference that the company’s science was never...

August 27 Medscape

How Safe Is Lifileucel After Patients Go Home?

The T-cell therapy’s inpatient toxicity is well-characterized, but the risks patients may face after hospital discharge have been unclear.

Never miss news about Iovance

Track Iovance and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Iovance competitors & trending companies

Browse news for competitors to Iovance and other trending companies.